All studies
RecruitingPhase I and Phase II (Integrated)- OtherInterventional

Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy

Small cell lung cancer can be aggressive, and it often returns after first-line platinum-based chemotherapy. When this happens, doctors need better treatment options. This clinical trial is testing a combination of two anti-cancer drugs: lurbinectedin (a chemotherapy drug) and atezolizumab (an immunotherapy that helps the body's natural defences fight cancer). The trial has two main stages. The first stage works out the safest dose of the two drugs to give together without causing unmanageable side effects. The second stage looks at how well this chosen dose works to shrink tumours or stop them from growing. Taking part involves having regular intravenous (drip) treatments at the hospital, alongside regular health checks and body scans every six weeks to monitor the cancer. The trial aims to discover whether combining these treatments offers a helpful new approach for people facing advanced lung cancer.

At a glance

Status
Recruiting
Phase
Phase I and Phase II (Integrated)- Other
Sponsor
Fundacion Oncosur
Enrolment target
140
Start
01 Oct 2024

What is this study about?

Small cell lung cancer is a fast-growing type of lung cancer. The usual first treatment is a platinum-based chemotherapy, which often works well at the start. However, the cancer frequently comes back or starts growing again after this initial therapy. When standard treatments stop working, doctors urgently need new, effective options to help keep the disease under control.

This trial investigates whether combining two different types of medicine can provide a better way forward. The first drug is lurbinectedin (also called PM01183), an anti-cancer drug designed to damage cancer cell DNA and stop tumours from growing. The second drug is atezolizumab (Tecentriq), an immunotherapy. Immunotherapy works by 'unmasking' cancer cells so that your own immune system can recognise and attack them. Researchers hope that using both medicines together will be more effective than using either one on its own.

Because this is an early-phase trial (combining Phase 1 and Phase 2), safety is the top priority. The first part of the study tests different amounts of the medicines to find the highest dose that is both safe and well tolerated. Once that ideal dose is found, the second part tests it in a larger group of people to measure how well it shrinks tumours and helps patients live longer with their disease under control.

By taking part, participants help doctors learn whether this combination could become a valuable new treatment option for people with advanced lung cancer across the UK and worldwide.

Key takeaways

  • Tests a combination of two drugs (lurbinectedin and atezolizumab) for small cell lung cancer.
  • Aimed at adults whose cancer has returned after initial platinum-based chemotherapy.
  • The first stage finds the safest dose, and the second stage tests how well it shrinks tumours.
  • Includes hospital visits for intravenous drips and regular body scans every six weeks.
  • Participation is entirely voluntary, and you can withdraw at any time.

Who may be eligible?

This trial is open to adults aged 18 and over who have been diagnosed with small cell lung cancer (either limited or extensive stage). To join, your cancer must have worsened or returned after you finished your first course of platinum-based chemotherapy, which is the standard initial treatment.

Doctors also need to be able to measure your cancer clearly on a scan, such as a CT or MRI scan. This is important so the research team can accurately track whether the treatment is shrinking your tumours or keeping them stable over time.

Your general health, organ function, and previous medical treatments will also be checked carefully by the study team. You might not be able to take part if you have certain other active medical conditions, severe ongoing side effects from past treatments, or if your doctor feels this trial is not the safest choice for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with small cell lung cancer.
  3. My cancer has returned or grown after previous platinum chemotherapy.
  4. I have measurable tumours that can be seen clearly on a CT or MRI scan.
  5. I am well enough to attend regular hospital appointments for drips and scans.
Answer every question to see your result.

What does participation involve?

Taking part involves receiving both trial medicines through a drip (infusion) into a vein at the hospital clinic. How often you receive the drips will depend on the study schedule, and your care team will explain this in detail before you start.

You will have regular hospital visits for safety checks, including physical examinations, blood tests, and heart monitoring. Before starting, you will have baseline scans, including a brain scan (CT or MRI) to check for any spread of cancer. During treatment, you will have body scans roughly every six weeks to see how your tumours are responding. Sometimes, immune treatments can cause a temporary swelling of tumours that looks like growth on scans even though the treatment is working; if you feel well, your doctor may allow you to continue treatment while monitoring this closely.

You can remain on the trial for as long as the treatment is helping you and the side effects remain manageable, or until you and your doctor decide it is best to stop. Total participation time varies for each person.

Potential risks and benefits

A potential benefit is that this combination could help shrink your lung cancer or slow its growth, and you will receive very close medical care from cancer specialists throughout the trial. However, there is no guarantee the treatment will work for you. Like all cancer therapies, these medicines carry risks of side effects. These can include extreme tiredness, sickness, reduced blood cell counts leading to an increased risk of infections, or immune-related inflammation affecting organs like the lungs, liver, or bowel. Your safety is monitored constantly, and medicines are available to help manage side effects. Taking part is completely voluntary, and you are free to leave the trial at any time without it affecting your standard NHS care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Spain

Common questions

What is the difference between chemotherapy and immunotherapy?

Chemotherapy works by directly attacking and killing rapidly dividing cancer cells. Immunotherapy works differently by boosting your own immune system so your body can recognise and fight the cancer cells itself.

Will I have to pay for the trial treatments?

No. In the UK, the trial medicines and any extra tests required for the study are provided free of charge.

What happens if my scans show the cancer is growing?

Your doctor will look closely at your overall health. Sometimes, immunotherapy can cause tumours to swell temporarily before shrinking (called pseudoprogression). If you feel well, your doctor might continue the treatment. If the cancer is truly growing, the study treatment will stop and other options will be discussed.

Can I leave the study if the side effects are too much?

Yes. You have the right to leave the trial at any point, for any reason. Your medical team will support your decision and arrange the best alternative treatment for you.

Do I have to stay overnight in the hospital?

Usually, treatments and check-ups are done during day visits in the outpatient clinic. Overnight stays are generally only needed if you become unwell or need extra observation.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Phase I-II Study to Assess the Safety, Tolerability and Effi…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.